Categories Earnings, Other Industries

UnitedHealth Group reports Q2 earnings above estimates

UnitedHealth Group (UNH) reported revenues of $56.1 billion for the second quarter of 2018, a 12% increase year-over-year. Net earnings attributable to UnitedHealth Group common shareholders was $2.92 billion or $2.98 per share. Adjusted EPS totaled $3.14 for the quarter. Both GAAP and adjusted EPS grew 28% year-over-year.

The earnings came above market expectation, though revenue was just on par with it. The stock dropped 1.2% premarket following the earnings release.

UnitedHealth raised its outlook for full-year 2018 GAAP EPS to a range of $11.80 to $12.05 per share and adjusted EPS to a range of $12.50 to $12.75 per share. The company expects cash flow from operations to reach $15.5 billion for 2018.

UnitedHealth second quarter 2018 earnings
UnitedHealth Group Q2 2018 Earnings Infographic

Consolidated medical care ratio of 81.9% fell 30 BP year-over-year, as the return of the health insurance tax more-than-offset business mix changes and reduced levels of prior-year reserve development during the second quarter. Days claims payable decreased one day sequentially to 48 days while days sales outstanding decreased one day sequentially to 18 days during Q2 2018.

In the UnitedHealthcare segment, net customer growth during the second quarter was 2.2 million. Total revenues grew over 12% driven by an increasing number of people served, a higher revenue membership mix, price increases to cover medical cost trends and resumption of the health insurance tax for this year. UnitedHealthcare Global revenues grew 33.5% year-over-year to $2.5 billion aided by business expansion.

UnitedHealth Group paid $866 million in dividends during the second quarter. This reflected an increase in the annual dividend payment rate by 20% to $3.60 per share in June 2018.

Related: UnitedHealth Group Incorporated Q2 2018 Earnings Call Transcript

Related: UnitedHealth Q1 2018 Earnings Infographic

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top